Table 1.
Baseline characteristics.
| All patients (n = 55) | |
|---|---|
| N (%) | |
| Gender (f/m) | 28/27 (51/49) |
| Comorbidities | |
| Coronary heart disease | 10 (18.2%) |
| Unknown: 4 (7.5%) | |
| History of MI | 5 (9.1%) |
| CABG | 6 (10.9%) |
| Arterial hypertension | 37 (67%) |
| Diabetes mellitus | 13 (23.6) |
| Medication | |
| Vitamin K-Antagonist | 40 (72%) |
| ASS | 10 (18.2%) |
| Beta-blocker | 21 (38.2%) |
| ACE inhibitor | 24 (43.6%) |
| AT1 blockers | 7 (12.7%) |
| Aldosterone antagonist | 24 (43.6%) |
| Diuretics | 44 (80%) |
| Amiodoaron | 10 (18.2%) |
| Calcium channel blocker | 3 (5.5%) |
| Digitoxin/Digoxin | 3/2 (5.5/3.6%) |
| Cardiac devices | |
| Cardiac pacemaker | 3 (5.5%) |
| Indication | Bradyarrhythmia absoluta (n = 1), sick sinus syndrome (n = 1), bradycardia/tachycardia syndrome (n = 1) |
| ICD | 2 (3.6%) |
| Indication | Primary prevention |
MI: myocardial infarction, CABG: coronary artery bypass graft, ACE: angiotensin converting enzyme, AT1: angiotensin 1, and ICD: implantable cardioverter defibrillator.